# Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

> **NCT01825395** · — · APPROVED_FOR_MARKETING · sponsor: **University of Colorado, Denver**

## Conditions studied

- Lambert Eaton Myasthenic Syndrome

## Interventions

- **DRUG:** 3, 4-Diaminopyridine

## Key facts

- **NCT ID:** NCT01825395
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01825395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01825395, "Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01825395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*